An intranasal vaccine designed to provide rapid, stable protection against anthrax after a single administration. It is being developed with the support of the U.S. Biomedical Advanced Research and Development Authority, (“BARDA”) for post-exposure prophylaxis against anthrax following exposure to aerosolized B. anthracis spores.
After an individual has been exposed to the spores that cause anthrax, B. anthracis bacteria multiply and release toxins within the host. Although antibiotic therapy is effective at eliminating the actively growing bacteria, vaccination is necessary to protect against the germination of dormant spores after the cessation of antibiotic therapy. Because NasoShield is intended to protect against anthrax after a single intranasal dose, it is a convenient and simple alternative to the only approved vaccine, which must be given as a series of three injections over 1 month. The simplified immunization route and schedule, together with the excellent stability at ambient temperature may allow NasoShield to be deployed in a anthrax event more easily and faster than the currently approved vaccine.